New antileishmanial candidates and lead compounds

Current Opinion in Chemical Biology

Volumn 14, Issue 4, 2010, Pages 447-455

  Richard, Julian V ^a   Werbovetz, Karl A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYLUNULARIN; 4 ARYLCOUMARIN; 8 AMINOQUINOLINE DERIVATIVE; ALKYLPHOSPHOCHOLINE; AMIODARONE; AMLODIPINE; AMODIAQUINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; AROMATIC NITRO COMPOUND; ARYLIMIDAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CHALCONE; DB 766; HYDROXYUREA; IVERMECTIN; LACIDIPINE; MILTEFOSINE; NAPHTHYLISOQUINOLINE; NPC 1161; PAROMOMYCIN; PYRAZINAMIDE; PYRIMIDINE DERIVATIVE; RHODACYANINE DYE; SITAMAQUINE; TRIAZINE DERIVATIVE; TRIFLURALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASICINE;

ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; HEMOLYSIS; HUMAN; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; LOW DRUG DOSE; MACROPHAGE; METHEMOGLOBINEMIA; NONHUMAN; REVIEW; SKIN LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIASIS; MOLECULAR STRUCTURE;

ANIMALIA;

EID: 77955333692     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.03.023     Document Type: Review

References (54)

1. Leishmaniasis - magnitude of the problem on World Wide Web URL: http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html.
2. Olliaro P., Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009, 14:88-92.
3. Berman J. Development of miltefosine for the leishmaniases. Minirev Med Chem 2006, 6:145-151.
4. Kumar D., Kulshrestha A., Singh R., Salotra P. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 2009, 53:835-838.
5. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., Olliaro P., Murray H. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008, 47:1000-1006.
6. Sundar S., Agrawal N., Arora R., Agarwal D., Rai M., Chakravarty J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis 2009, 49:914-918.
7. Ben Salah A., Buffet P., Morizot G., Ben Massoud N., Zâatour A., Ben Alaya N., Hamida N., El Ahmadi Z., Downs M., Smith P., et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009, 3:e432.
8. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R., Alvar J., Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol 2007, 5:873-882.
9. Palumbo E. Current treatment for cutaneous leishmaniasis: a review. Am J Therapeutics 2009, 16:178-182.
10. Kedzierski L., Sakthianandeswaren A., Curtis J., Andrews P., Junk P., Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 2009, 16:599-614.
11. Cavalli A., Bolognesi M. Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem 2009, 52:7339-7359.
12. Vermeersch M., da Luz R., Toté K., Timmermans J., Cos P., Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 2009, 53:3855-3859.
13. Calogeropoulou T., Angelou P., Detsi A., Fragiadaki I., Scoulica E. Design and synthesis of potent antileishmanial cycloalkylidene-substituted ether phospholipid derivatives. J Med Chem 2008, 51:897-908.
14. Coghi P., Vaiana N., Pezzano M., Rizzi L., Kaiser M., Brun R., Romeo S. Parallel synthesis and antileishmanial activity of ether-linked phospholipids. Bioorg Med Chem Lett 2008, 18:4658-4660.
15. 2+ homeostasis and biosynthesis of sterols in Leishmania mexicana. Antimicrob Agents Chemother 2009, 53:1403-1410.
16. Serrano-Martín X., Payares G., De Lucca M., Martinez J., Mendoza-León A., Benaim G. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 2009, 53:5108-5113.
17. Kayser O., Olbrich C., Yardley V., Kiderlen A., Croft S. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003, 254:73-75.
18. Wasan K., Wasan E., Gershkovich P., Zhu X., Tidwell R., Werbovetz K., Clement J., Thornton S. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009, 200:357-360.
19. Pierson J., Dumètre A., Hutter S., Delmas F., Laget M., Finet J., Azas N., Combes S. Synthesis and antiprotozoal activity of 4-arylcoumarins. Eur J Med Chem 2010, 45:864-869.
20. Hu L., Arafa R., Ismail M., Wenzler T., Brun R., Munde M., Wilson W., Nzimiro S., Samyesudhas S., Werbovetz K., et al. Azaterphenyl diamidines as antileishmanial agents. Bioorg Med Chem Lett 2008, 18:247-251.
21. Wang M, Zhu X, Srivastava A, Liu Q, Sweat J, Pandharkar T, Stephens C, Riccio E, Mandal S, Madhubala R, et al.: Novel arylimidamides for the treatment of visceral leishmaniasis. Antimicrob Agents Chemother (in press), doi:10.1128/AAC.00250-10.
22. Yardley V., Khan A., Martin M., Slifer T., Araujo F., Moreno S., Docampo R., Croft S., Oldfield E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother 2002, 46:929-931.
23. Singh U., Shankar R., Kumar A., Trivedi R., Chattopadhyay N., Shakya N., Palne S., Gupta S., Hajela K. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents. Bioorg Med Chem 2008, 16:8482-8491.
24. Chen M., Christensen S., Theander T., Kharazmi A. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother 1994, 38:1339-1344.
25. Suryawanshi S., Chandra N., Kumar P., Porwal J., Gupta S. Chemotherapy of leishmaniasis part VIII: synthesis and bioevaluation of novel chalcones. Eur J Med Chem 2008, 43:2473-2478.
26. Rechwald C., Shimony O., Dunkel U., Sacerdoti-Sierra N., Jaffe C., Kunick C. 2-(3-Aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype. J Med Chem 2008, 51:659-665.
27. Palit P., Ali N. Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2008, 52:374-377.
28. Roldos V., Nakayama H., Rolón M., Trucco F., Torres S., Vega C., Marrero-Ponce Y., Heguaburu V., Yaluff G., Gómez-Barrio A., et al. Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem 2008, 43:1797-1807.
29. Martinez-Rojano H., Mancilla-Ramirez J., Quiñonez-Diaz L., Galindo-Sevilla N. Activity of hydroxyurea against Leishmania mexicana. Antimicrob Agents Chemother 2008, 52:3642-3647.
30. dos Santos A., Falcão C., Muzitano M., Kaiser C., Rossi-Bergmann B., Férézou J. Ivermectin-derived leishmanicidal compounds. Bioorg Med Chem 2009, 17:496-502.
31. Delfín D., Morgan R., Zhu X., Werbovetz K. Redox-active dinitrophenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies. Bioorg Med Chem 2009, 17:820-829.
32. Chan M., Fong D. Inhibition of Leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science 1990, 249:924-926.
33. Esteves M., Fragiadaki I., Lopes R., Scoulica E., Cruz M. Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents. Bioorg Med Chem 2010, 18:274-281.
34. Behrouzi-Fardmoghadam M., Poorrajab F., Ardestani S., Emami S., Shafiee A., Foroumadi A. Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines. Bioorg Med Chem 2008, 16:4509-4515.
35. Poorajab F., Ardestani S., Emami S., Behrouzi-Fardmoghadam M., Shafiee A., Foroumadi A. Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation. Eur J Med Chem 2009, 44:1758-1762.
36. Jaafari M., Bavarsad N., Fazly Bazzaz B., Samiei A., Soroush D., Ghorbani S., Lotfi Heravi, Khamesipour A. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2009, 53:2259-2265.
37. Khaliq T., Misra P., Gupta S., Reddy K., Kant R., Maulik P., Dube A., Narender T. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett 2009, 19:2585-2586.
38. Mendez S., Traslavina R., Hinchman M., Huang L., Green P., Cynamon M., Welch J. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother 2009, 53:5114-5121.
39. Sunduru N., Nishi, Palne S., Chauhan P., Gupta S. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. Eur J Med Chem 2009, 44:2473-2481.
40. Agarwal K., Sharma V., Shakya N., Gupta S. Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents. Bioorg Med Chem Lett 2009, 19:5474-5477.
41. LaMontagne M., Dagli D., Khan S., Blumbergs P. Analogues of 8-[[6-diethylamino)hexyl]amino]-6-methoxy-4-methylquinoline as candidate antileishmanial agents. J Med Chem 1980, 23:981-985.
42. Sherwood J., Gachihi G., Muiagi R., Skillman D., Mugo M., Rashid J., Wasunna K., Were J., Kasili S., Mbugua J., et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994, 19:1034-1039.
43. Jha T., Sundar S., Thakur C., Felton J., Sabin A., Horton J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005, 73:1005-1011.
44. Nanayakkara N., Ager A., Bartlett S., Yardley V., Croft S., Khan I., McChesney J., Walker L. Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob Agents Chemother 2008, 52:2130-2137.
45. Guglielmo S., Bertinaria M., Rolando B., Crosetti M., Fruttero R., Yardley V., Croft S., Gasco A. A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur J Med Chem 2009, 44:5071-5079.
46. Bringmann G., Brun R., Kaiser M., Neumann S. Synthesis and antiprotozoal activities of simplified analogs of naphthylisoquinoline alkaloids. Eur J Med Chem 2008, 43:32-42.
47. Ponte-Sucre A., Gulder T., Wegehaupt A., Albert C., Rikanovic C., Schaeflein L., Frank A., Schultheis M., Unger M., Holzgrabe U., et al. Structure-activity relationship and studies on the molecular mechanism of leishmanicidal N,C-coupled arylisoquinolinium salts. J Med Chem 2009, 52:626-636.
48. Palit P., Paira P., Hazra A., Banerjee S., Gupta A., Dastidar S., Mondal N. Phase transfer catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation. Eur J Med Chem 2009, 44:845-853.
49. Yang M., Arai C., Bakar A., Lu J., Ge J., Pudhom K., Takasu K., Kasai K., Kaiser M., Brun R., et al. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL). J Med Chem 2010, 53:368-373.
50. Fernandes Rodrigues J., Concepcion J., Rodrigues C., Caldera A., Urbina J., de Souza W. In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob Agents Chemother 2008, 52:4098-4114.
51. Srinivas N., Palne S., Nishi, Gupta S., Bhandari K. Aryloxy cyclohexyl imidazoles: a novel class of antileishmanial agents. Bioorg Med Chem Lett 2009, 19:324-327.
52. Bhandari K., Srinivas N., Marrapu V., Verma A., Srivastava S., Gupta S. Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as antileishmanial agents. Bioorg Med Chem Lett 2010, 20:291-293.
53. Croft S., Yardley V. Animal models of visceral leishmaniasis. Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy 1999, Academic Press, 783-787.
54. Melby P., Chandrasekar B., Zhao W., Coe J. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 2001, 166:1912-1920.